MARKET

VIRI

VIRI

Virios Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.900
0.000
0.00%
Closed 16:00 05/06 EDT
OPEN
4.830
PREV CLOSE
4.900
HIGH
4.970
LOW
4.800
VOLUME
12.53K
TURNOVER
--
52 WEEK HIGH
16.71
52 WEEK LOW
4.600
MARKET CAP
38.38M
P/E (TTM)
-4.2256
1D
5D
1M
3M
1Y
5Y
Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, 2021
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its first quarter 2021 ...
Business Wire · 1d ago
Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Interview with Chairman and CEO of Virios Therapeutics, Inc. to Air on Bloomberg Television on the RedChip Money Report
Business Wire · 04/16 12:05
Virios Therapeutics to Present at the Needham Virtual Healthcare Conference
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman a...
Business Wire · 04/07 12:05
We're Hopeful That Virios Therapeutics (NASDAQ:VIRI) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 03/30 14:29
10-K: VIRIOS THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/23 17:44
Virios Therapeutics reports Q4 results
Virios Therapeutics (VIRI): Q4 GAAP EPS of -$1.25.Cash totaled $29.8MPress Release
Seekingalpha · 03/18 12:09
Virios Therapeutics Inc to Host Earnings Call
ACCESSWIRE · 03/18 11:30
Virios Therapeutics Q4 EPS $(1.25) Down From $(0.13) YoY
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(1.25) per share. This is a 861.54 percent decrease over losses of $(0.13) per share from the same period last year.
Benzinga · 03/18 11:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIRI. Analyze the recent business situations of Virios Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIRI stock price target is 15.00 with a high estimate of 15.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 9
Institutional Holdings: 605.79K
% Owned: 7.73%
Shares Outstanding: 7.83M
TypeInstitutionsShares
Increased
0
0
New
9
605.79K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VIRI
Virios Therapeutics LLC is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. IMC-1 combines two specific mechanisms of action purposely designed to inhibit HSV-1 activation and replication, thereby keeping HSV-1 in a latent (dormant) state or down-regulating HSV-1 from a lytic (active) state back to latency. The famciclovir component of IMC-1 inhibits viral DNA replication and thus inhibits upregulation of the HSV-1 virus. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (COX-2) and to a lesser degree COX-1, enzymes used by HSV-1 to amplify or accelerate its own replication.

Webull offers kinds of Virios Therapeutics LLC stock information, including NASDAQ:VIRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRI stock methods without spending real money on the virtual paper trading platform.